Vaxart, Inc.
385 Oyster Point #9A
South San Francisco
California
94080
United States
Website: http://www.vaxart.com/
121 articles about Vaxart, Inc.
-
Vaxart to Present at the Jefferies Virtual Healthcare Conference
6/3/2020
Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced today announced that Wouter Latour, MD, chief executive officer of Vaxart is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:00 p.m. Eastern Time. Jefferies Virtual Health
-
Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
5/20/2020
KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
-
Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update
5/12/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.
-
Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine ProgramRobust Boosting of Immune Responses Observed after Second Dose
4/30/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose. “These pre-clinical results confirm that all constructs are immunogeni
-
Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th
4/28/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2020 financial results after the Nasdaq Global Market close on Tuesday, May 12, 2020. About Catabasis At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for
-
Vaxart Announces Corporate Update for First Quarter 2020
4/28/2020
Preparations for the Manufacturing of GMP Vaccine at Emergent BioSolutions Ongoing Vaxart is Participating in Maxim’s Infectious Disease Virtual Conference on May 5, 2020 SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today provided an update on its financials for the first quarter of 2020, and a corporate update ahead of its
-
Clinical Catch-Up: April 20-24
4/27/2020
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look. -
Bay Area-based Vaxart, Inc. has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose.
-
Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine ProgramLead Vaccine Candidates Generate Anti-SARS CoV-2 Antibodies in All Tested Animals after First Dose
4/21/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose. “These early pre-clinical results are in line with those for our oral
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Vaxart Provides Update on its Oral COVID-19 Vaccine Program
3/31/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it had produced five COVID-19 vaccine candidates for testing in its preclinical models.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
-
Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
3/19/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.
-
Vaxart Announces It Entered Into An Agreement With Emergent Biosolutions For The Development And Manufacturing Of Oral Coronavirus (Covid-19) Vaccine Candidate
3/18/2020
Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine
-
Emergent Biosolutions Signs Development And Manufacturing Agreement With Vaxart For Their Experimental Oral Vaccine Candidate For Coronavirus Disease
3/18/2020
Emergent BioSolutions Inc. announced that it has entered into an agreement with Vaxart, Inc., a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease.
-
Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market
2/27/2020
Vaxart, Inc. announced that it has entered into definitive agreements with several institutional investors for the issuance and sale of 4,000,000 shares of its common stock and warrants to purchase up to 2,000,000 shares of its common stock, at a combined purchase price of $2.50 per share and associated warrant, for aggregate gross proceeds of $10.0 million, in a registered direct offering priced at-the-market under Nasdaq rules.
-
Vaxart Announces Initiation of Coronavirus Vaccine Program Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine
1/31/2020
Vaxart, Inc. (NasdaqGS: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that it has initiated a program to develop a coronavirus vaccine candidate based on its proprietary oral vaccine platform, VAAST.
-
Clinical Catch-Up: Jan 20-24
1/27/2020
The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look.